Citigroup Inc. Has $3.25 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Posted by on Sep 5th, 2023

Citigroup Inc. raised its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 85.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 188,719 shares of the company’s stock after buying an additional 86,785 shares during the period. Citigroup Inc. owned 0.32% of Zentalis Pharmaceuticals worth $3,246,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZNTL. State Street Corp boosted its position in Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company’s stock valued at $87,665,000 after buying an additional 1,039,294 shares in the last quarter. Avidity Partners Management LP lifted its position in shares of Zentalis Pharmaceuticals by 21.9% during the fourth quarter. Avidity Partners Management LP now owns 5,150,000 shares of the company’s stock worth $103,721,000 after purchasing an additional 926,900 shares in the last quarter. Mayo Clinic acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $5,984,000. Federated Hermes Inc. lifted its position in shares of Zentalis Pharmaceuticals by 22.7% during the first quarter. Federated Hermes Inc. now owns 1,486,998 shares of the company’s stock worth $25,576,000 after purchasing an additional 275,398 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $4,672,000.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, major shareholder Matrix Capital Management Comp bought 4,760,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Tuesday, June 20th. The stock was acquired at an average price of $22.66 per share, for a total transaction of $107,861,600.00. Following the completion of the acquisition, the insider now owns 13,959,973 shares of the company’s stock, valued at approximately $316,332,988.18. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ZNTL has been the topic of a number of research reports. Stifel Nicolaus upped their target price on shares of Zentalis Pharmaceuticals from $45.00 to $50.00 in a research report on Wednesday, June 7th. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $51.00 to $50.00 and set an “overweight” rating on the stock in a research report on Thursday, August 10th. Jefferies Financial Group reduced their target price on shares of Zentalis Pharmaceuticals from $120.00 to $70.00 in a research report on Friday, May 19th. Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, August 10th. Finally, HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, August 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $47.50.

View Our Latest Report on ZNTL

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $27.14 on Tuesday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -5.65 and a beta of 1.78. The firm has a 50 day simple moving average of $26.71 and a 200 day simple moving average of $23.54. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $15.55 and a fifty-two week high of $31.49.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.82). During the same period in the prior year, the company earned ($1.34) EPS. As a group, analysts expect that Zentalis Pharmaceuticals, Inc. will post -4.79 EPS for the current year.

About Zentalis Pharmaceuticals

(Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.